Here are four insights:
1. PhRMA backs Ms. Clinton’s plan to cap a patient’s share of a drug’s cost at $250 each month.
2. PhRMA, however, strongly opposes Ms. Clinton’s plan to fight high drug costs.
3. While Clinton’s proposal does not impact a drug’s full price, it does force the insurance company to pay a larger portion of the cost.
4. PhRMA CEO Stephen Ubl said the group understands patients often face obstacles accessing their medicine due to high prices.
More articles on quality & infection control:
Pennsylvania Patient Safety Authority names new executive director — 5 highlights
Senate pushing more medical bills forward: 5 notes
Community Health Worker model yields better outcomes for patients in outpatient settings — 4 things to know
